|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SERHL2 |
Gene summary for SERHL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SERHL2 | Gene ID | 253190 |
| Gene name | serine hydrolase like 2 | |
| Gene Alias | dJ222E13.1 | |
| Cytomap | 22q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9H4I8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 253190 | SERHL2 | GSM4909289 | Human | Breast | IDC | 4.40e-28 | 1.30e+00 | 0.1064 |
| 253190 | SERHL2 | GSM4909290 | Human | Breast | IDC | 2.54e-05 | 3.51e-01 | 0.2096 |
| 253190 | SERHL2 | GSM4909294 | Human | Breast | IDC | 1.52e-21 | 7.40e-01 | 0.2022 |
| 253190 | SERHL2 | GSM4909317 | Human | Breast | IDC | 1.09e-16 | 5.66e-01 | 0.1355 |
| 253190 | SERHL2 | brca3 | Human | Breast | Precancer | 9.90e-11 | 4.30e-01 | -0.0263 |
| 253190 | SERHL2 | NCCBC11 | Human | Breast | DCIS | 2.68e-02 | 4.35e-01 | 0.1232 |
| 253190 | SERHL2 | NCCBC6 | Human | Breast | DCIS | 3.19e-19 | 1.29e+00 | 0.2095 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SERHL2 | SNV | Missense_Mutation | c.634N>A | p.Gln212Lys | p.Q212K | Q9H4I8 | protein_coding | tolerated(0.2) | benign(0.009) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| SERHL2 | SNV | Missense_Mutation | rs754746774 | c.886N>A | p.Val296Met | p.V296M | Q9H4I8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SERHL2 | SNV | Missense_Mutation | rs199630766 | c.874N>A | p.Glu292Lys | p.E292K | Q9H4I8 | protein_coding | tolerated(0.31) | benign(0.029) | TCGA-AG-3894-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| SERHL2 | SNV | Missense_Mutation | c.167N>T | p.Pro56Leu | p.P56L | Q9H4I8 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERHL2 | SNV | Missense_Mutation | c.73N>G | p.Lys25Glu | p.K25E | Q9H4I8 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-A5-A0GQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERHL2 | SNV | Missense_Mutation | c.383T>G | p.Leu128Arg | p.L128R | Q9H4I8 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SERHL2 | SNV | Missense_Mutation | rs771070052 | c.689C>T | p.Ala230Val | p.A230V | Q9H4I8 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SERHL2 | SNV | Missense_Mutation | rs199630766 | c.874N>A | p.Glu292Lys | p.E292K | Q9H4I8 | protein_coding | tolerated(0.31) | benign(0.029) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SERHL2 | SNV | Missense_Mutation | novel | c.354N>A | p.Phe118Leu | p.F118L | Q9H4I8 | protein_coding | deleterious(0) | benign(0.003) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| SERHL2 | SNV | Missense_Mutation | rs771070052 | c.689N>T | p.Ala230Val | p.A230V | Q9H4I8 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AX-A2H8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |